NCT02743741进行中（未招募）不适用
A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment With Individualized Dosimetry in Patients With 68Ga-DOTATATE Identified Somatostatin Receptor Positive Neuroendocrine Tumors
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 195
- 试验地点
- 4
- 主要终点
- The proportion of patients progression-free using RECIST 1.1 criteria
研究概览
简要总结
This is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by 68Ga-DOTATATE. 195 patients will be enrolled totally. Patient who has progressed with neuroendocrine tumor will be evaluated by the tumor board first and eligible patients will undergo diagnostic Ga 68 PET scan. Patients who showed Somatostatin will undergo 4 cycles of Lu-DOTATATE treatment. Dose adjustment for Cycle 2-4 will be made based on individualized dosimetry, as well as creatinine clearance and hematological parameters. Patients will be evaluated progression free survival at 12 months from last dose. Patients who are negative for somatostatin will not receive 68Ga-DOTATATE treatment but will be followed until progression and acts as control group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Biopsy-proven neuroendocrine tumor
- •ECOG performance status ≤ 2
- •Ki-67 index ≤ 30%
- •Evidence of progressive disease demonstrated by imaging within six months prior to study enrollment as defined by RECIST v1.
- •Tumor board discussion of cases to confirm suitability for participation in the clinical trial is required. Review should include but not limited to imaging review, pathology (including Ki 67) and treatment options.
- •Patients with objective evidence (imaging, or biochemical) that is insufficient to be classified by RECIST 1.1 criteria can be eligible if after provincial multidisciplinary tumor board discussion a consensus for progression eligibility is reached.
- •The tumor board would consider exemptions if the magnitude of change is adequate by other definitions (e.g. using structural and contrast patterns and biochemical changes).
- •Where clinically indicated, formal consultation on pathology, diagnostic imaging to facilitate criteria assessment (including 68Ga PET performed as part of the diagnostic procedure) is strongly recommended.
- •Adequate lab parameters within 2 weeks prior to enrollment:
- •Serum creatinine ≤ 150 μmol/L
- •Calculated CrCl or measured GFR ≥ 30 mL/min (measured GFR may be done within 4 weeks prior to enrollment)
- •Haemoglobin ≥ 90 g/L
- •WBC ≥ 2 x 109/L
- •Platelets ≥ 100 x 109/L
- •Adequate liver function tests within 2 weeks prior to enrollment:
- •total bilirubin ≤ 5 x ULN
- •ALT ≤ 5 x ULN
- •AST ≤ 5 x ULN
- •alkaline phosphatase ≤ 5 x ULN
- •Signed informed consent
- •Patients with extensive bone metastases (e.g. >25% of bone marrow involvement are eligible but requires careful monitoring of hematological reserve
- •Subject's willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
- •Age ≥ 18 years.
排除标准
- •Life expectancy <12 weeks
- •An option for curative surgical or medical therapy or local liver embolization is feasible
- •Candidate for curative and/or debulking surgical resections
- •Systemic, biologic, other radioisotope, embolization therapies within ≤4 weeks prior to the first dose of 177Lu.
- •Prior radiotherapy to target lesion(s) within ≤12 weeks prior to study enrollment [radiotherapy to non-target lesions permitted].
- •Prior therapy with any systemic radionuclide therapy.
- •Radiotherapy to more than 25% of the bone marrow.
- •Known brain metastases (unless metastases have been treated and are stable for ≥ 6 months).
- •Uncontrolled diabetes mellitus
- •Co-morbidities that may interfere with delivery of 177Lu (e.g. urinary incontinence).
- •Second cancer(s) with clinical or biochemical progression within the last 3 years.
- •Pregnancy or breast feeding. Female subjects must be surgically sterile or postmenopausal, or must agree to use effective contraception during the period of therapy. All female subjects with reproductive potential must have a negative pregnancy test (serum) prior to enrolment. Male subjects must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate
- •Other condition, illness, psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation, 68Ga or 177Lu administration, or may interfere with the interpretation of study results and in the judgment of the investigator would make the patient inappropriate for entry into this study.
研究组 & 干预措施
Lutetium-177 Octreotate
Experimental
Lutetium-177 Octreotate 200 mCi (7.4 GBq) by IV for 18-30 weeks
干预措施: Lutetium-177 Octreotate (Drug)
结局指标
主要结局
The proportion of patients progression-free using RECIST 1.1 criteria
时间窗: Up to 12 months
次要结局
- The Quality of Life (QoL) in patients treated with Lu-DOTATATE (177Lu)(Up to 5 years)
- The overall response rate as determined by structural imaging using RECIST criteria.(Up to 5 years)
- The biochemical response rate (as defined by biochemical responses: serum chromogranin A and 24 hr urinary 5HIAA).(Up to 5 years)
- The acute and late adverse effects of Lu-DOTATATE (177Lu) using CTCAE Version 4.03(Up to 5 years)
- Overall survival(Up to 5 years)
研究者
研究点 (4)
Loading locations...
相似试验
招募中
2 期
A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine NeoplasmsAdvanced Neuroendocrine NeoplasmNCT06398444Sinotau Pharmaceutical Group85
已完成
不适用
A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)Peripheral Arterial DiseaseCritical Limb IschemiaNCT05358353ReFlow Medical, Inc.130
Unknown
不适用
Clinical Trials of Pulsed Sonic Balloon Dilatation Catheter and Pulsed Sonic GeneraterCoronary Calcified DiseaseNCT05406869Lepu Medical Technology (Beijing) Co., Ltd.170
Unknown
不适用
Investigation of the Glaukos® Trabecular Micro-Bypass System, Model iS3, in Subjects With Refractory GlaucomaGlaucomaNCT03639870Glaukos Corporation65
招募中
不适用
A Clinical Trial to Evaluate the Safety and Efficacy of IBS Angel in Patients With Pulmonary Artery StenosisPulmonary Artery StenosisNCT04973540Biotyx Medical (Shenzhen) Co., Ltd.82